JPRN-UMIN000024339
Completed
未知
Intranasal Oxytocin for Autism Spectrum Disorder and Comorbid Severe Intellectual Disabilities:open-label study - Intranasal Oxytocin for Autism Spectrum Disorder and Comorbid Severe Intellectual Disabilities
ational Hospital Organization Hizen Psychiatric Center0 sites7 target enrollmentOctober 7, 2016
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Autism spectrum disorder severe intellectual disabilities
- Sponsor
- ational Hospital Organization Hizen Psychiatric Center
- Enrollment
- 7
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •CARS\-TV less than 30 points self\-standing position impossible Weighing less than 20kg History of status epilepticus Possibility of pregnancy Body exhaustion and advanced inspection value or more
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Intranasal Oxytocin for Autism Spectrum Disorder and Comorbid Severe Intellectual Disabilities:Open-label long term studyAutism Spectrum Disorder Severe intellectual disabilitiesJPRN-UMIN000028650ational Hospital Organization Hizen Psychiatric Center3
Recruiting
Phase 2
Oxytocin in Preschoolers with Autism receiving Social Learning TherapyAutism Spectrum DisordersMental Health - Autistic spectrum disordersACTRN12618001029280niversity of Sydney132
Active, not recruiting
Phase 1
The use of Oxytocin for Autism Spectrum Disorders: Investigating theeffect on behavior and at the level of the brain.Young male adults with Autism Spectrum Disorders (18-30 years)MedDRA version: 16.1Level: LLTClassification code 10003808Term: Autistic disorderSystem Organ Class: 100000004852Therapeutic area: Psychiatry and Psychology [F] - Psychological processes [F02]EUCTR2014-000586-45-BEKU Leuven40
Completed
Not Applicable
Intranasal Oxytocin for the Treatment of Autism Spectrum DisordersAutism Spectrum DisordersNCT01337687Montefiore Medical Center19
Completed
Phase 2
Single Dose Intranasal Oxytocin and Cognitive Effects in AutismAutism Spectrum DisordersNCT02493426University of Minnesota27